Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma.
Publication
, Journal Article
Fixsen, E; Patel, J; Kheterpal, M
Published in: Cutis
October 2022
Duke Scholars
Published In
Cutis
DOI
EISSN
2326-6929
Publication Date
October 2022
Volume
110
Issue
4
Start / End Page
E11 / E13
Location
United States
Related Subject Headings
- Scleroderma, Localized
- Nivolumab
- Lung Neoplasms
- Humans
- Dermatology & Venereal Diseases
- Adenocarcinoma of Lung
Citation
APA
Chicago
ICMJE
MLA
NLM
Fixsen, E., Patel, J., & Kheterpal, M. (2022). Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma. Cutis, 110(4), E11–E13. https://doi.org/10.12788/cutis.0637
Fixsen, Emma, Jigar Patel, and Meenal Kheterpal. “Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma.” Cutis 110, no. 4 (October 2022): E11–13. https://doi.org/10.12788/cutis.0637.
Fixsen E, Patel J, Kheterpal M. Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma. Cutis. 2022 Oct;110(4):E11–3.
Fixsen, Emma, et al. “Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma.” Cutis, vol. 110, no. 4, Oct. 2022, pp. E11–13. Pubmed, doi:10.12788/cutis.0637.
Fixsen E, Patel J, Kheterpal M. Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma. Cutis. 2022 Oct;110(4):E11–E13.
Published In
Cutis
DOI
EISSN
2326-6929
Publication Date
October 2022
Volume
110
Issue
4
Start / End Page
E11 / E13
Location
United States
Related Subject Headings
- Scleroderma, Localized
- Nivolumab
- Lung Neoplasms
- Humans
- Dermatology & Venereal Diseases
- Adenocarcinoma of Lung